$NB
NIOCORP DEVELOPMENTS LTD Stock $nb

$nb Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000153949723001700 Filed on October 06, 2023

Income Statement

Concept	2023 Q4	2023 Q2	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.280M	$2.330M	$4.900M
YoY Change	131.46%	423.6%	72.9%
% of Gross Profit
Research & Development	$828.0K	$1.330M	$5.350M
YoY Change	-37.13%	-1.63%	61.68%
% of Gross Profit
Depreciation & Amortization	$1.000K	$0.00	$3.000K
YoY Change		-100.0%	0.0%
% of Gross Profit
Operating Expenses	$2.917M	$3.940M	$37.41M
YoY Change	32.53%	85.32%	379.86%
Operating Profit
YoY Change
Interest Expense	$1.176M	-$750.0K	$2.336M
YoY Change	1334.15%	31.81%	22.56%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$3.387M	-$4.690M	-$40.61M
YoY Change	53.4%	74.03%	309.0%
Income Tax		-$120.0K	-$304.0K
% Of Pretax Income
Net Earnings	-$3.387M	-$4.430M	-$40.31M
YoY Change	53.4%	64.38%	305.96%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.10	-$0.15	-$1.40
COMMON SHARES
Basic Shares Outstanding	32.91M shares	30.40M shares	28.71M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023 Q2	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$634.0K	$2.340M	$2.340M
YoY Change	49.53%	-55.68%	-55.68%
Cash & Equivalents	$634.0K	$2.341M	$2.340M
Short-Term Investments
Other Short-Term Assets	$432.0K	$1.390M	$1.390M
YoY Change	285.71%	245.77%	245.77%
Inventory
Prepaid Expenses		$1.385M
Receivables
Other Receivables
Total Short-Term Assets	$1.066M	$3.726M	$3.730M
YoY Change	98.88%	-34.42%	-34.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.13M	$839.0K	$17.16M
YoY Change	0.88%	-1.29%	0.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$7.000K	$10.00K	$10.00K
YoY Change	-22.22%	0.0%	0.0%
Other Assets	$35.00K	$40.00K	$40.00K
YoY Change	-99.2%	14.29%	14.29%
Total Long-Term Assets	$17.17M	$17.20M	$17.20M
YoY Change	-19.62%	0.76%	0.74%
TOTAL ASSETS
Total Short-Term Assets	$1.066M	$3.726M	$3.730M
Total Long-Term Assets	$17.17M	$17.20M	$17.20M
Total Assets	$18.24M	$20.93M	$20.93M
YoY Change	-16.72%	-8.02%	-8.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.001M	$3.491M	$1.990M
YoY Change	441.41%	2935.65%	1630.43%
Accrued Expenses	$936.0K	$252.0K	$1.470M
YoY Change	-18.96%	0.0%	87.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Long-Term Debt Due	$5.506M	$0.00	$0.00
YoY Change	996.81%	-100.0%	-100.0%
Total Short-Term Liabilities	$11.70M	$3.562M	$3.560M
YoY Change	65.0%	-3.6%	-3.65%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$10.56M	$10.56M
YoY Change
Other Long-Term Liabilities	$3.040M	$4.989M	$15.67M
YoY Change		21591.3%	68030.43%
Total Long-Term Liabilities	$3.040M	$4.989M	$26.23M
YoY Change		21591.3%	113943.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.70M	$3.562M	$3.560M
Total Long-Term Liabilities	$3.040M	$4.989M	$26.23M
Total Liabilities	$22.49M	$29.80M	$31.90M
YoY Change	217.33%	701.43%	757.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$157.0M	-$150.5M
YoY Change	36.32%	38.05%
Common Stock	$151.8M	$140.4M
YoY Change	15.89%	8.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.082M	-$10.97M	-$10.97M
YoY Change
Total Liabilities & Shareholders Equity	$18.24M	$20.93M	$20.93M
YoY Change	-16.72%	-8.02%	-8.02%

Cashflow Statement

Concept	2023 Q4	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$3.387M	-$4.430M	-$40.31M
YoY Change	53.4%	64.38%	305.96%
Depreciation, Depletion And Amortization	$1.000K	$0.00	$3.000K
YoY Change		-100.0%	0.0%
Cash From Operating Activities	-$1.885M	-$5.830M	-$17.30M
YoY Change	-21.0%	235.83%	181.22%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$20.00K
YoY Change
Cash From Investing Activities		$0.00	$21.00K
YoY Change			-231.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$2.499M
YoY Change			-47.25%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.428M	1.020M	$14.64M
YoY Change	-371.48%	-72.02%	240.32%
NET CHANGE
Cash From Operating Activities	-1.885M	-5.830M	-$17.30M
Cash From Investing Activities		0.000	$21.00K
Cash From Financing Activities	1.428M	1.020M	$14.64M
Net Change In Cash	-457.0K	-4.810M	-$2.939M
YoY Change	-84.19%	-351.83%	44.28%
FREE CASH FLOW
Cash From Operating Activities	-$1.885M	-$5.830M	-$17.30M
Capital Expenditures		$0.00	$0.00
Free Cash Flow		-$5.830M	-$17.30M
YoY Change		235.83%	181.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	niobf	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability		usd
CY2022	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount		usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001512228
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023Q2	niobf	Due To Officers Or Stockholders Other Current DueToOfficersOrStockholdersOtherCurrent		usd
CY2023Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent		usd
CY2022Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent		usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent		usd
CY2022Q2	niobf	Earnout Liability At Fair Value EarnoutLiabilityAtFairValue		usd
CY2022Q2	us-gaap	Redeemable Noncontrolling Interest Equity Other Carrying Amount RedeemableNoncontrollingInterestEquityOtherCarryingAmount		usd
CY2023	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022	niobf	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability		usd
CY2021	niobf	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability		usd
CY2022	niobf	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability		usd
CY2022	us-gaap	Other Income OtherIncome		usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings		usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2022	us-gaap	Oci Equity Method Investment Before Tax Noncontrolling Interest OciEquityMethodInvestmentBeforeTaxNoncontrollingInterest		usd
CY2021	us-gaap	Oci Equity Method Investment Before Tax Noncontrolling Interest OciEquityMethodInvestmentBeforeTaxNoncontrollingInterest		usd
CY2022	niobf	Assumption Of Earnout Liability AssumptionOfEarnoutLiability		usd
CY2021	niobf	Assumption Of Earnout Liability AssumptionOfEarnoutLiability		usd
CY2022	niobf	Change In Fair Value Of Earnout Share Liability ChangeInFairValueOfEarnoutShareLiability		usd
CY2021	niobf	Change In Fair Value Of Earnout Share Liability ChangeInFairValueOfEarnoutShareLiability		usd
CY2022	niobf	Assumption Of Private And Public Warrants AssumptionOfPrivateAndPublicWarrants		usd
CY2021	niobf	Assumption Of Private And Public Warrants AssumptionOfPrivateAndPublicWarrants		usd
CY2022	niobf	Losses On Extinguishment Of Debt LossesOnExtinguishmentOfDebt		usd
CY2022	niobf	Change In Valuation Of Warrant Liabilities ChangeInValuationOfWarrantLiabilities		usd
CY2021	niobf	Change In Valuation Of Warrant Liabilities ChangeInValuationOfWarrantLiabilities		usd
CY2022	niobf	Fair Value Of Commitment Shares Issued FairValueOfCommitmentSharesIssued		usd
CY2021	niobf	Fair Value Of Commitment Shares Issued FairValueOfCommitmentSharesIssued		usd
CY2021	us-gaap	Depreciation Depreciation		usd
CY2022	niobf	Otheroperating Gains Losses OtheroperatingGainsLosses		usd
CY2023	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss		usd
CY2022	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss		usd
CY2023	us-gaap	Payments To Acquire Mineral Rights PaymentsToAcquireMineralRights		usd
CY2022	us-gaap	Payments To Acquire Mineral Rights PaymentsToAcquireMineralRights		usd
CY2023	us-gaap	Payments To Acquire Buildings PaymentsToAcquireBuildings		usd
CY2022	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets		usd
CY2021	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets		usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	niobf	Recognition Of Operating Lease Liabilities RecognitionOfOperatingLeaseLiabilities
CY2023	niobf	Derecognition Of Operating Lease Liabilities DerecognitionOfOperatingLeaseLiabilities
CY2022	niobf	Derecognition Of Operating Lease Liabilities DerecognitionOfOperatingLeaseLiabilities
CY2023	niobf	Accounts Payable To Convertible Debt Conversion AccountsPayableToConvertibleDebtConversion
CY2022	niobf	Accounts Payable To Convertible Debt Conversion AccountsPayableToConvertibleDebtConversion
CY2022	niobf	Value Of Warrants Issued ValueOfWarrantsIssued
CY2023	niobf	Common Shares Issued In The Gxii Transaction CommonSharesIssuedInTheGXIITransaction		usd
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	228000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest		usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest		usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3877000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3877000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-35076000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-40308000	usd
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31202131	shares
CY2022Q2	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent		usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Fair Value Disclosure AccountsPayableAndAccruedLiabilitiesFairValueDisclosure		usd
CY2023Q2	us-gaap	Long Term Debt Term LongTermDebtTerm	P24M
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	215	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
CY2022	niobf	Amounts Advanced AmountsAdvanced		usd
CY2023Q2	us-gaap	Related Party Deposit Liabilities RelatedPartyDepositLiabilities		usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	252000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	873000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P3Y7M6D
CY2022Q2	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P1Y3M19D
CY2023	us-gaap	Exploration Costs ExplorationCosts		usd
CY2022	us-gaap	Exploration Costs ExplorationCosts		usd
CY2022	niobf	Earnout Shares Liability EarnoutSharesLiability		usd
CY2021	niobf	Earnout Shares Liability EarnoutSharesLiability		usd
CY2022	niobf	Warrant Liability WarrantLiability		usd
CY2021	niobf	Warrant Liability WarrantLiability		usd
CY2022	niobf	Gxii Transaction Costs GxiiTransactionCosts		usd
CY2021	niobf	Gxii Transaction Costs GxiiTransactionCosts		usd
CY2022	us-gaap	Extinguishment Of Debt Gain Loss Income Tax ExtinguishmentOfDebtGainLossIncomeTax		usd
CY2021	us-gaap	Extinguishment Of Debt Gain Loss Income Tax ExtinguishmentOfDebtGainLossIncomeTax		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-304000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q2	niobf	Deferred Tax Assets Startup And Oorganizational Costs DeferredTaxAssetsStartupAndOorganizationalCosts		usd
CY2022Q2	niobf	Deferred Tax Assets Research And Development Costs DeferredTaxAssetsResearchAndDevelopmentCosts		usd
CY2022Q2	niobf	Deferred Tax Assets Share Issuance Costs DeferredTaxAssetsShareIssuanceCosts		usd
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	us-gaap	Costs Incurred Development Costs CostsIncurredDevelopmentCosts		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-55710
CY2023	dei	Entity Registrant Name EntityRegistrantName	NioCorp Developments Ltd.
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1262185
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	7000 South Yosemite Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 115
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Centennial
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80112
CY2023	dei	City Area Code CityAreaCode	(720)
CY2023	dei	Local Phone Number LocalPhoneNumber	334-7066
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Public Float EntityPublicFloat	190700000	usd
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32913419	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2341000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5280000	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1385000	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	402000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	3726000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	5682000	usd
CY2023Q2	us-gaap	Deposits Assets DepositsAssets	35000	usd
CY2022Q2	us-gaap	Deposits Assets DepositsAssets	35000	usd
CY2023Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	9000	usd
CY2022Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	10000	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	236000	usd
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	94000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	839000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	850000	usd
CY2023Q2	us-gaap	Capitalized Costs Mineral Interests In Unproved Properties CapitalizedCostsMineralInterestsInUnprovedProperties	16085000	usd
CY2022Q2	us-gaap	Capitalized Costs Mineral Interests In Unproved Properties CapitalizedCostsMineralInterestsInUnprovedProperties	16085000	usd
CY2023Q2	us-gaap	Assets Assets	20930000	usd
CY2022Q2	us-gaap	Assets Assets	22756000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3491000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	817000	usd
CY2022Q2	niobf	Due To Officers Or Stockholders Other Current DueToOfficersOrStockholdersOtherCurrent	2000000	usd
CY2022Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	2169000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	71000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	82000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3562000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	5068000	usd
CY2023Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	10561000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4989000	usd
CY2023Q2	niobf	Earnout Liability At Fair Value EarnoutLiabilityAtFairValue	10521000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	164000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	29797000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	5091000	usd
CY2023Q2	us-gaap	Redeemable Noncontrolling Interest Equity Other Carrying Amount RedeemableNoncontrollingInterestEquityOtherCarryingAmount	2100000	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31202131	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27667060	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	140421000	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	129055000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-150477000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110397000	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-911000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-993000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-10967000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	17665000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20930000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22756000	usd
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	2323000	usd
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	2150000	usd
CY2021	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1655000	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	2581000	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	684000	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	386000	usd
CY2023	niobf	Exploration Expenditures ExplorationExpenditures	5348000	usd
CY2022	niobf	Exploration Expenditures ExplorationExpenditures	3309000	usd
CY2021	niobf	Exploration Expenditures ExplorationExpenditures	1056000	usd
CY2023	us-gaap	Other General Expense OtherGeneralExpense	27158000	usd
CY2022	us-gaap	Other General Expense OtherGeneralExpense	1653000	usd
CY2021	us-gaap	Other General Expense OtherGeneralExpense	995000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	37410000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	7796000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	4092000	usd
CY2023	niobf	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	2674000	usd
CY2023	niobf	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-1414000	usd
CY2023	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	1922000	usd
CY2021	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	163000	usd
CY2023	us-gaap	Interest Expense InterestExpense	2336000	usd
CY2022	us-gaap	Interest Expense InterestExpense	2827000	usd
CY2021	us-gaap	Interest Expense InterestExpense	1543000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-216000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-258000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	725000	usd
CY2023	us-gaap	Other Income OtherIncome	13000	usd
CY2021	us-gaap	Other Income OtherIncome	208000	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	32000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-1000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-6000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	9000	usd
CY2023	niobf	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest1 IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest1	-40612000	usd
CY2022	niobf	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest1 IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest1	-10887000	usd
CY2021	niobf	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest1 IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest1	-4824000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-304000	usd
CY2023	niobf	Profit Loss1 ProfitLoss1	-40308000	usd
CY2022	niobf	Profit Loss1 ProfitLoss1	-10887000	usd
CY2021	niobf	Profit Loss1 ProfitLoss1	-4824000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	228000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-40080000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-10887000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-4824000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-40308000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10887000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-4824000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-82000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-166000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	804000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40226000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10721000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5628000	usd
CY2023	us-gaap	Oci Equity Method Investment Before Tax Noncontrolling Interest OciEquityMethodInvestmentBeforeTaxNoncontrollingInterest	228000	usd
CY2023	us-gaap	Oci Equity Method Investment Before Tax Parent OciEquityMethodInvestmentBeforeTaxParent	-39998000	usd
CY2022	us-gaap	Oci Equity Method Investment Before Tax Parent OciEquityMethodInvestmentBeforeTaxParent	-10721000	usd
CY2021	us-gaap	Oci Equity Method Investment Before Tax Parent OciEquityMethodInvestmentBeforeTaxParent	-5628000	usd
CY2023	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	1.34
CY2022	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	0.41
CY2021	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	0.20
CY2023	niobf	Total Weighted Average Number Of Share Outstanding Basic And Diluted TotalWeightedAverageNumberOfShareOutstandingBasicAndDiluted	28705840000	usd
CY2022	niobf	Total Weighted Average Number Of Share Outstanding Basic And Diluted TotalWeightedAverageNumberOfShareOutstandingBasicAndDiluted	26373722000	usd
CY2021	niobf	Total Weighted Average Number Of Share Outstanding Basic And Diluted TotalWeightedAverageNumberOfShareOutstandingBasicAndDiluted	24196711000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-40308000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10887000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-4824000	usd
CY2023	niobf	Assumption Of Earnout Liability AssumptionOfEarnoutLiability	13195000	usd
CY2023	niobf	Change In Fair Value Of Earnout Share Liability ChangeInFairValueOfEarnoutShareLiability	-2674000	usd
CY2023	niobf	Assumption Of Private And Public Warrants AssumptionOfPrivateAndPublicWarrants	2987000	usd
CY2023	us-gaap	Accretion Expense AccretionExpense	2157000	usd
CY2022	us-gaap	Accretion Expense AccretionExpense	2619000	usd
CY2021	us-gaap	Accretion Expense AccretionExpense	1100000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1794000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1745000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	797000	usd
CY2023	niobf	Losses On Extinguishment Of Debt LossesOnExtinguishmentOfDebt	1422000	usd
CY2021	niobf	Losses On Extinguishment Of Debt LossesOnExtinguishmentOfDebt	163000	usd
CY2023	niobf	Change In Valuation Of Warrant Liabilities ChangeInValuationOfWarrantLiabilities	1414000	usd
CY2023	niobf	Fair Value Of Commitment Shares Issued FairValueOfCommitmentSharesIssued	663000	usd
CY2023	niobf	Foreign Currency Transaction Gain Loss Before Tax1 ForeignCurrencyTransactionGainLossBeforeTax1	200000	usd
CY2022	niobf	Foreign Currency Transaction Gain Loss Before Tax1 ForeignCurrencyTransactionGainLossBeforeTax1	329000	usd
CY2021	niobf	Foreign Currency Transaction Gain Loss Before Tax1 ForeignCurrencyTransactionGainLossBeforeTax1	-661000	usd
CY2023	us-gaap	Depreciation Depreciation	3000	usd
CY2022	us-gaap	Depreciation Depreciation	3000	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1000	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-6000	usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	9000	usd
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	-12000	usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	-7000	usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	30000	usd
CY2023	niobf	Otheroperating Gains Losses OtheroperatingGainsLosses	13000	usd
CY2021	niobf	Otheroperating Gains Losses OtheroperatingGainsLosses	196000	usd
CY2021	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	32000	usd
CY2023	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-19171000	usd
CY2022	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-6192000	usd
CY2021	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-3632000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	985000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	377000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-9000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2861000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	419000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1103000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17295000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6150000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4726000	usd
CY2021	us-gaap	Payments To Acquire Mineral Rights PaymentsToAcquireMineralRights	5468000	usd
CY2022	us-gaap	Payments To Acquire Buildings PaymentsToAcquireBuildings	16000	usd
CY2021	us-gaap	Payments To Acquire Buildings PaymentsToAcquireBuildings	837000	usd
CY2023	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	21000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	21000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6305000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	14857000	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	9477000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2499000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4737000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10677000	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1130000	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	3130000	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	318000	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1500000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	515000	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	406000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	204000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	118000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	174000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14637000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4301000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18074000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-302000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-172000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-33000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2939000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2037000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7010000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5280000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7317000	usd
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	307000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2341000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5280000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7317000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	264000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	252000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	873000	usd
CY2023	niobf	Conversions Of Debt For Common Shares ConversionsOfDebtForCommonShares	5,175
CY2022	niobf	Conversions Of Debt For Common Shares ConversionsOfDebtForCommonShares	8,807
CY2021	niobf	Conversions Of Debt For Common Shares ConversionsOfDebtForCommonShares	3,106
CY2023	niobf	Recognition Of Operating Lease Liabilities RecognitionOfOperatingLeaseLiabilities	199
CY2021	niobf	Recognition Of Operating Lease Liabilities RecognitionOfOperatingLeaseLiabilities	231
CY2021	niobf	Derecognition Of Operating Lease Liabilities DerecognitionOfOperatingLeaseLiabilities	(22
CY2021	niobf	Accounts Payable To Convertible Debt Conversion AccountsPayableToConvertibleDebtConversion	1,640
CY2023	niobf	Value Of Warrants Issued ValueOfWarrantsIssued	3,337
CY2021	niobf	Value Of Warrants Issued ValueOfWarrantsIssued	1,795
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2641000	usd
CY2021	niobf	Stock Issued During Period Shares Stock Warrant Exercised StockIssuedDuringPeriodSharesStockWarrantExercised	5338000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	215000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1795000	usd
CY2021	niobf	Private Placement Value May2021 PrivatePlacementValueMay2021	5124000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	3106000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-175000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	797000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-804000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-4824000	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13213000	usd
CY2022	niobf	Stock Issued During Period Shares Stock Warrant Exercised StockIssuedDuringPeriodSharesStockWarrantExercised	543000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	483000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	14000	usd
CY2022	niobf	Private Placement Shares May2021 PrivatePlacementSharesMay2021	3711000	shares
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	8807000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-130000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1745000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	166000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-10887000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17665000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11000	usd
CY2023	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	3338000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	650000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	2000000	usd
CY2023	niobf	Shares Issued Under The Yorkville Equity Facility SharesIssuedUnderTheYorkvilleEquityFacility	501000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	5604000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-204000	usd
CY2023	niobf	Redeemable Noncontrolling Interest RedeemableNoncontrollingInterest	-2328000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1794000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	82000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-40080000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-10967000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80F_eus-gaap--NatureOfOperations_zj6YcLTXPR5l" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td id="xdx_82D_zxkIhqU1ACo6" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF BUSINESS</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NioCorp Developments Ltd. (the “Company” or “NioCorp”) was incorporated on February 27, 1987, under the laws of the Province of British Columbia and currently operates in <span id="xdx_901_eus-gaap--NumberOfReportableSegments_dxL_uNUMBER_c20220701__20230630_zifKldeWzKTc" title="Number of reportable segments::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl0709">one</span></span> reportable operating segment consisting of exploration and development of mineral deposits in North America, specifically, the Elk Creek Niobium/Scandium/Titanium property (the “Elk Creek Project”) located in southeastern Nebraska.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As further discussed in Notes 5, 9, 10, and 11, on March 17, 2023 (the “Closing Date”), the Company closed the GXII Transaction (as defined below) with GX Acquisition Corp. II (“GXII”), pursuant to the Business Combination Agreement, dated September 25, 2022 (the “Business Combination Agreement”), among the Company, GXII and Big Red Merger Sub Ltd (the “Closing”). At the Closing, the Company also closed convertible debt financings (the “Yorkville Convertible Debt Financing”) with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP (together with YA II PN, Ltd., “Yorkville”), and the standby equity purchase facility with Yorkville (the “Yorkville Equity Facility Financing” and, together with the Yorkville Convertible Debt Financing, the “Yorkville Financings”) became effective. The transactions contemplated by the Business Combination Agreement, including the GXII Transaction, the Yorkville Financings and the Reverse Stock Split (as defined below), are referred to, collectively, as the “Transactions.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The GXII Transaction is being accounted for as an equity raise transaction in accordance with generally accepted accounting principles of the United States of America (“U.S. GAAP”). Under this method of accounting, GXII is treated as the “acquired” company for financial reporting purposes. Accordingly, the GXII Transaction is treated as the equivalent of NioCorp issuing common shares, no par value, of the Company (“Common Shares”) for the assets and liabilities of GXII. The net assets of GXII are stated at historical cost, with no goodwill or other intangible assets recorded.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These consolidated financial statements have been prepared on a going concern basis that contemplates the realization of assets and discharge of liabilities at their carrying values in the normal course of business for the foreseeable future. These consolidated financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently earns no operating revenues and will require additional capital in order to advance the Elk Creek Project to construction and commercial operation. As further discussed in Note 4, these matters raised substantial doubt about the Company’s ability to continue as a going concern, and the Company is dependent upon the generation of profits from mineral properties, obtaining additional financing and maintaining continued support from its shareholders and creditors.</span></p>
CY2023	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_80A_eus-gaap--BasisOfAccounting_zQYcL4w1vx82" style="margin-top: 0; margin-bottom: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_82E_zIsB8ZEsQrHd">BASIS OF PREPARATION</span></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis of Preparation and Consolidation</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These consolidated financial statements have been prepared in conformity with U.S. GAAP and the rules and regulations of the U.S. Securities and Exchange Commission. The consolidated financial statements include the consolidated accounts of the Company and its wholly owned subsidiaries with all significant intercompany transactions eliminated. Certain transactions include reference to Canadian dollars (“C$”) where applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0"> </p> <div style="text-align: center; margin-left: 0.25in"></div> <p style="margin-top: 0; margin-bottom: 0; margin-left: 0.25in"><b></b></p> <p style="margin-top: 0; margin-bottom: 0; margin-left: 0.25in"> </p> <p id="xdx_895_eus-gaap--ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_zj4H0tKNxq02" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These consolidated financial statements include the accounts of the Company and the subsidiaries listed in the following table. All intercompany transactions and balances have been eliminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span><span id="xdx_8B6_zfL7KyGUoM14" style="display: none; visibility: hidden">Schedule of intercompany transactions and balances</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td rowspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td rowspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jurisdiction of incorporation</b></span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership at June 30,</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 41%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0896800 BC Ltd. (“0896800”)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--IncorporationStateCountryName_c20220701__20230630__srt--OwnershipAxis__custom--Entity0896800BCLtdMember_zQmMSWJijxzi" title="Country of incorporation"><span id="xdx_908_ecustom--IncorporationStateCountryName_c20210701__20220630__srt--OwnershipAxis__custom--Entity0896800BCLtdMember_zGlmuRZxB341" title="Country of incorporation">British Columbia, Canada</span></span></span></td> <td id="xdx_98B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230630__srt--OwnershipAxis__custom--Entity0896800BCLtdMember_zzbIweDCVVoa" style="font: 10pt Times New Roman, Times, Serif; width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center" title="Percentage of ownership"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td> <td id="xdx_981_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20220630__srt--OwnershipAxis__custom--Entity0896800BCLtdMember_zzc9JvGhtq87" style="font: 10pt Times New Roman, Times, Serif; width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center" title="Percentage of ownership"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 0.375in; text-align: justify; text-indent: -23.4pt; width: 41%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elk Creek Resources Corp.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--IncorporationStateCountryName_c20220701__20230630__srt--OwnershipAxis__custom--ElkCreekResourcesCorpMember_zksiovUNC0i9" title="Country of incorporation"><span id="xdx_906_ecustom--IncorporationStateCountryName_c20210701__20220630__srt--OwnershipAxis__custom--ElkCreekResourcesCorpMember_zkUMxkHVlFL6" title="Country of incorporation">Nebraska, USA</span></span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 17%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 17%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20220630__srt--OwnershipAxis__custom--ElkCreekResourcesCorpMember_ziAzFfl1yeQ9" title="Percentage of ownership">100</span>% by 0896800</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elk Creek Resources Corp. (“ECRC”)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_ecustom--IncorporationStateCountryName_c20220701__20230630__srt--OwnershipAxis__custom--ElkCreekResourcesCorpECRCMember_zZnDPIi8PWTd" title="Country of incorporation"><span id="xdx_905_ecustom--IncorporationStateCountryName_c20210701__20220630__srt--OwnershipAxis__custom--ElkCreekResourcesCorpECRCMember_zJpRKSrWeSmk" title="Country of incorporation">Delaware, USA</span></span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_uPure_c20230630__srt--OwnershipAxis__custom--ElkCreekResourcesCorpECRCMember_zwP0I9QOW6dl" title="Percentage of ownership">100</span>% of the Class A common stock by 0896800</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0; margin-left: 0.25in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Estimates</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuations, convertible debt valuations, earnout valuation, warrant liabilities, and share-based compensation. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between estimates and the actual results, future results of operations will be affected. </span></p>
CY2022Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	48000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_z4EOR7m4rotd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86D_zoVOqAKsMn4c">Concentration of Credit Risk</span></span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial instrument which potentially subjects the Company to credit risk is cash and cash equivalents, The Company holds investments or maintains available cash primarily in two commercial banks located in Vancouver,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p> <p style="margin-top: 0; margin-bottom: 0"> </p> <div style="text-align: center; margin-left: 0.25in"></div> <p style="margin-top: 0; margin-bottom: 0; margin-left: 0.25in"><b></b></p> <p style="margin-top: 0; margin-bottom: 0; margin-left: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">British Columbia and Santa Clara, California. As part of its cash management process, the Company regularly monitors the relative credit standing of these institutions.</span></p>
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	48000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-40308000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10887000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-4824000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	40057000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	10887000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4824000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1528000	usd
CY2023	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	38529000	usd
CY2022	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	10887000	usd
CY2021	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	4824000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28705840	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26373722	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24196711	shares
CY2023	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	1.34
CY2022	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	0.41
CY2021	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	0.20
CY2023	us-gaap	Incremental Common Shares Attributable To Written Put Options IncrementalCommonSharesAttributableToWrittenPutOptions	1541500	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Written Put Options IncrementalCommonSharesAttributableToWrittenPutOptions	1446400	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Written Put Options IncrementalCommonSharesAttributableToWrittenPutOptions	1596500	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	18816304	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1851622	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1434186	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2871660	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	415200	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	1455700	shares
CY2023	us-gaap	Dilutive Securities DilutiveSecurities	23229464000	usd
CY2022	us-gaap	Dilutive Securities DilutiveSecurities	3713222000	usd
CY2021	us-gaap	Dilutive Securities DilutiveSecurities	4486386000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_849_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zp4sRsVfdp0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in">r)</td><td style="text-align: left"><span id="xdx_86D_zfPv1ZxtiDKj">Revision of Financial Statements (Unaudited)</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in">During the fourth quarter of fiscal year 2023, the Company determined that it had used an incorrect strike price while valuing the Private Warrants (as defined below in Note 11c) at both the March 17, 2023, issuance date and as of March 31, 2023. This resulted in an overstatement of other operating expenses, at fair value, and an understatement of change in fair value of warrant liabilities in condensed consolidated statement of operations and comprehensive loss for both the three- and nine-month periods ended March 31, 2023. In addition, warrant liabilities, at fair value and accumulated deficit were overstated and understated, respectively, as of March 31, 2023. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company determined that these errors were immaterial to the previously issued consolidated financial statements, and as such no restatement was necessary. Periods not presented herein will be revised, as applicable, in future filings.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in">The effects of the revision on the previously issued consolidated financial statements are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"> </p> <p id="xdx_896_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zhsVYVtVC4s6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Revision Impacts to the Condensed Consolidated Balance Sheet (unaudited)</b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As of March 31, 2023</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_8BB_zqPDmNb9cDEc" style="display: none; visibility: hidden">Revision Impacts to the Condensed Consolidated Balance Sheet (unaudited) As of March 31, 2023</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zelflEE9IMBf" style="font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zWaKgukSfI9" style="font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230331_zY93igpGJPta" style="font-weight: bold; text-align: right"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">As Previously<br/> Reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">Revision<br/> Impacts</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">Revised</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherLiabilitiesNoncurrent_iI_pn3n3_zqax1sPZZ8hd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: left; padding-left: 5.4pt">Warrant liabilities, at fair value</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,303</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(665</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4,638</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Total liabilities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--Liabilities_iI_pn3n3_c20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zRJ4DvEAlRkk" style="text-align: right" title="Total liabilities">34,735</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--Liabilities_iNI_pn3n3_di_c20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zCy0TdbKQsH" style="text-align: right" title="Total liabilities">(665</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--Liabilities_iI_pn3n3_c20230331_zxCnuRnyJIEi" style="text-align: right" title="Total liabilities">34,070</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pn3n3_z1kI0YlWdhE3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Accumulated deficit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(146,046</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">665</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(145,381</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--StockholdersEquity_iI_pn3n3_zEeGmVLayfV2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Total shareholders’ deficit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(12,512</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">665</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,847</td><td style="text-align: left">)</td></tr> </table> <p id="xdx_8A2_zXr0M4XmAGXb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"></p> <p id="xdx_89B_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zf4thyh0OZk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Revision Impacts to the Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Three Months Ended March 31, 2023</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_8B8_zwMYtoPoRhJ1" style="display: none; visibility: hidden">Revision Impacts to the Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited) For the Three & Nine Months Ended March 31, 2023</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">As Previously<br/> Reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">Revision<br/> Impacts</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">Revised</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; text-align: left; padding-left: 5.4pt">Other operating expense</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--OtherGeneralExpense_pn3n3_c20230101__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zgQOUnHXWm68" style="width: 12%; text-align: right" title="Other operating expense">26,220</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--OtherGeneralExpense_iN_pn3n3_di_c20230101__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zpLsguPTVOxc" style="width: 12%; text-align: right" title="Other operating expense">(861</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--OtherGeneralExpense_pn3n3_c20230101__20230331_zasjIfkHG88d" style="width: 12%; text-align: right" title="Other operating expense">25,359</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Total operating expenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingExpenses_pn3n3_c20230101__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zMubrwz0kZt3" style="text-align: right" title="Total operating expenses">29,192</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingExpenses_pn3n3_c20230101__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zH8djFst0Oeh" style="text-align: right" title="Total operating expenses">(861</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--OperatingExpenses_pn3n3_c20230101__20230331_zXe8FrzG6AT7" style="text-align: right" title="Total operating expenses">28,331</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Change in fair value of warrant liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiability_iN_pn3n3_di_c20230101__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zKTc1llfKIEk" style="text-align: right" title="Change in fair value of warrant liability">784</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ChangeInFairValueOfWarrantLiability_iN_pn3n3_di_c20230101__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zKLUQIW7L7g4" style="text-align: right" title="Change in fair value of warrant liability">196</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ChangeInFairValueOfWarrantLiability_iN_pn3n3_di_c20230101__20230331_zBKidsx6iaqj" style="text-align: right" title="Change in fair value of warrant liability">980</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Loss before income taxes</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_c20230101__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zkop0E3nssMi" style="text-align: right" title="Loss before income taxes">29,621</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_c20230101__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zefaGBWcanv1" style="text-align: right" title="Loss before income taxes">(665</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_dxL_c20230101__20230331_zTUVmm3EVvbc" style="text-align: right" title="Loss before income taxes::XDX::-3877"><span style="-sec-ix-hidden: xdx2ixbrl0929">28,956</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Net loss</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zDEONR6tVaG5" style="text-align: right" title="Net loss">29,435</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zTzxnU9qsx3d" style="text-align: right" title="Net loss">(665</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--NetIncomeLoss_pn3n3_c20230101__20230331_zTXUUlkWJVU3" style="text-align: right" title="Net loss">28,770</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Net loss attributable to the Company</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ProfitLoss1_pn3n3_c20230101__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zzG310e4baTk" style="text-align: right" title="Net loss attributable to the company">29,343</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ProfitLoss1_pn3n3_c20230101__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zTNbjnxJqVt6" style="text-align: right" title="Net loss attributable to the company">(665</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ProfitLoss1_pn3n3_c20230101__20230331_zGms76QML6g2" style="text-align: right" title="Net loss attributable to the company">28,678</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Total comprehensive loss</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ComprehensiveIncomeNetOfTax_pn3n3_c20230101__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zCkWs19aZdeh" style="text-align: right" title="Total comprehensive loss">29,323</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ComprehensiveIncomeNetOfTax_pn3n3_c20230101__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zPIBX74Xw4Z1" style="text-align: right" title="Total comprehensive loss">(665</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ComprehensiveIncomeNetOfTax_pn3n3_c20230101__20230331_z9Alax3TgdJ2" style="text-align: right" title="Total comprehensive loss">28,658</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Comprehensive loss attributable to the Company</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OciEquityMethodInvestmentBeforeTaxParent_pn3n3_c20230101__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zyDqlX3Y74x6" style="text-align: right" title="Comprehensive loss attributable to the company">29,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--OciEquityMethodInvestmentBeforeTaxParent_pn3n3_c20230101__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zG6JE1rlwC6a" style="text-align: right" title="Comprehensive loss attributable to the company">(665</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--OciEquityMethodInvestmentBeforeTaxParent_pn3n3_c20230101__20230331_z2L0neTwcTSc" style="text-align: right" title="Comprehensive loss attributable to the company">28,566</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Loss per common share, basic and diluted</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_ecustom--EarningsLossPerShareBasicAndDiluted_pid_uUSDPShares_c20230101__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zNILCmuSVGma" style="text-align: right" title="Loss per common share, basic and diluted">1.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_ecustom--EarningsLossPerShareBasicAndDiluted_pid_uUSDPShares_c20230101__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zlpch4MOAPo4" style="text-align: right" title="Loss per common share, basic and diluted">(0.02</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--EarningsLossPerShareBasicAndDiluted_pid_uUSDPShares_c20230101__20230331_z1FzQUrq6b97" style="text-align: right" title="Loss per common share, basic and diluted">0.98</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="margin-top: 0; margin-bottom: 0"> </p> <p style="margin-top: 0; margin-bottom: 0; margin-left: 0.25in"><b></b></p> <p style="margin-top: 0; margin-bottom: 0; margin-left: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Revision Impacts to the Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Nine Months Ended March 31, 2023 </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td style="width: 55%; padding-bottom: 1pt; padding-left: 5.4pt"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; background-color: white; padding-right: 1.45pt"> </td> <td style="width: 12%; background-color: white; padding-right: 1.45pt; text-align: right"> </td> <td style="width: 1%; background-color: white; padding-bottom: 1pt"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; background-color: white; padding-right: 1.45pt"> </td> <td style="width: 12%; background-color: white; padding-right: 1.45pt; text-align: right"> </td> <td style="width: 1%; background-color: white; padding-bottom: 1pt"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="width: 1%; background-color: white; padding-right: 1.45pt"> </td> <td style="width: 12%; background-color: white; padding-right: 1.45pt; text-align: right"> </td> <td style="width: 1%; background-color: white; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; padding-left: 5.4pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; background-color: white; padding-right: 1.45pt"> </td> <td style="border-bottom: black 1pt solid; background-color: white; padding-right: 1.45pt; text-align: right"><span style="font-size: 10pt"><b>As Previously<br/> Reported</b></span></td> <td style="border-bottom: black 1pt solid; background-color: white; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; background-color: white; padding-right: 1.45pt"> </td> <td style="border-bottom: black 1pt solid; background-color: white; padding-right: 1.45pt; text-align: right"><span style="font-size: 10pt"><b>Revision<br/> Impacts</b></span></td> <td style="border-bottom: black 1pt solid; background-color: white; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; background-color: white; padding-right: 1.45pt"> </td> <td style="border-bottom: black 1pt solid; background-color: white; padding-right: 1.45pt; text-align: right"><span style="font-size: 10pt"><b>Revised</b></span></td> <td style="background-color: white; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 5.4pt"><span style="font-size: 10pt">Other operating expense</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_985_eus-gaap--OtherGeneralExpense_pn3n3_c20220701__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zYqCHLJxMxO9" style="padding-right: 1.45pt; text-align: right" title="Other operating expense"><span style="font-size: 10pt">26,888</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_98C_eus-gaap--OtherGeneralExpense_iN_pn3n3_di_c20220701__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_z9N7AAiEK2a2" style="padding-right: 1.45pt; text-align: right" title="Other operating expense"><span style="font-size: 10pt">(861</span></td> <td style="padding-right: 1.45pt"><span style="font-size: 10pt">)</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_98B_eus-gaap--OtherGeneralExpense_pn3n3_c20220701__20230331_zKeufiUYm8qe" style="padding-right: 1.45pt; text-align: right" title="Other operating expense"><span style="font-size: 10pt">26,027</span></td> <td style="padding-right: 1.45pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt"><span style="font-size: 10pt">Total operating expenses</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_98B_eus-gaap--OperatingExpenses_pn3n3_c20220701__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zPqhiQylMFh6" style="padding-right: 1.45pt; text-align: right" title="Total operating expenses"><span style="font-size: 10pt">33,475</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_98F_eus-gaap--OperatingExpenses_pn3n3_c20220701__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zOnwEy7ElEg" style="padding-right: 1.45pt; text-align: right" title="Total operating expenses"><span style="font-size: 10pt">(861</span></td> <td style="padding-right: 1.45pt"><span style="font-size: 10pt">)</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_987_eus-gaap--OperatingExpenses_pn3n3_c20220701__20230331_z3rjgMQXLo2c" style="padding-right: 1.45pt; text-align: right" title="Total operating expenses"><span style="font-size: 10pt">32,614</span></td> <td style="padding-right: 1.45pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF"> <td style="padding-left: 5.4pt"><span style="font-size: 10pt">Change in fair value of warrant liability</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_98E_ecustom--ChangeInFairValueOfWarrantLiability_iN_pn3n3_di_c20220701__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zGRArvNXlvyg" style="padding-right: 1.45pt; text-align: right" title="Change in fair value of warrant liability"><span style="font-size: 10pt">868</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_98B_ecustom--ChangeInFairValueOfWarrantLiability_iN_pn3n3_di_c20220701__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_ze6iLON1bLq2" style="padding-right: 1.45pt; text-align: right" title="Change in fair value of warrant liability"><span style="font-size: 10pt">196</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_989_ecustom--ChangeInFairValueOfWarrantLiability_iN_pn3n3_di_c20220701__20230331_zuXbyNA31H96" style="padding-right: 1.45pt; text-align: right" title="Change in fair value of warrant liability"><span style="font-size: 10pt">1,064</span></td> <td style="padding-right: 1.45pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt"><span style="font-size: 10pt">Loss before income taxes</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_981_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_c20220701__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zYWQlY66Wnz5" style="padding-right: 1.45pt; text-align: right" title="Loss before income taxes"><span style="font-size: 10pt">35,927</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_982_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_c20220701__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zpRhxZjqEyEd" style="padding-right: 1.45pt; text-align: right" title="Loss before income taxes"><span style="font-size: 10pt">(665</span></td> <td style="padding-right: 1.45pt"><span style="font-size: 10pt">)</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_981_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_dxL_c20220701__20230331_zWnUuOx7nh73" style="padding-right: 1.45pt; text-align: right" title="Loss before income taxes::XDX::-3877"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0988">35,262</span></span></td> <td style="padding-right: 1.45pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF"> <td style="padding-left: 5.4pt"><span style="font-size: 10pt">Net loss</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_98A_eus-gaap--NetIncomeLoss_pn3n3_dxL_c20220701__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z9qjusG3RCWk" style="padding-right: 1.45pt; text-align: right" title="Net loss::XDX::-35741"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0990">35,741</span></span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_980_eus-gaap--NetIncomeLoss_pn3n3_dxL_c20220701__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zmIztkbqaAhc" style="padding-right: 1.45pt; text-align: right" title="Net loss::XDX::665"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0992">(665</span></span></td> <td style="padding-right: 1.45pt"><span style="font-size: 10pt">)</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_98A_eus-gaap--NetIncomeLoss_pn3n3_dxL_c20220701__20230331_z4nx268bQSIk" style="padding-right: 1.45pt; text-align: right" title="Net loss::XDX::-35076"><span style="font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0994">35,076</span></span></td> <td style="padding-right: 1.45pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt"><span style="font-size: 10pt">Net loss attributable to the Company</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_981_ecustom--ProfitLoss1_pn3n3_c20220701__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zm2e8LNnCqnj" style="padding-right: 1.45pt; text-align: right" title="Net loss attributable to the company"><span style="font-size: 10pt">35,649</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_98A_ecustom--ProfitLoss1_pn3n3_c20220701__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zYuXfcMAfHIc" style="padding-right: 1.45pt; text-align: right" title="Net loss attributable to the company"><span style="font-size: 10pt">(665</span></td> <td style="padding-right: 1.45pt"><span style="font-size: 10pt">)</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_985_ecustom--ProfitLoss1_pn3n3_c20220701__20230331_z9sJmKZ4oxMk" style="padding-right: 1.45pt; text-align: right" title="Net loss attributable to the company"><span style="font-size: 10pt">34,984</span></td> <td style="padding-right: 1.45pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF"> <td style="padding-left: 5.4pt"><span style="font-size: 10pt">Total comprehensive loss</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_980_eus-gaap--ComprehensiveIncomeNetOfTax_pn3n3_c20220701__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zKA82dNJQKfk" style="padding-right: 1.45pt; text-align: right" title="Total comprehensive loss"><span style="font-size: 10pt">35,659</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_98A_eus-gaap--ComprehensiveIncomeNetOfTax_pn3n3_c20220701__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zZ5L3oKr2MW1" style="padding-right: 1.45pt; text-align: right" title="Total comprehensive loss"><span style="font-size: 10pt">(665</span></td> <td style="padding-right: 1.45pt"><span style="font-size: 10pt">)</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_986_eus-gaap--ComprehensiveIncomeNetOfTax_pn3n3_c20220701__20230331_zcGBegKbF1yh" style="padding-right: 1.45pt; text-align: right" title="Total comprehensive loss"><span style="font-size: 10pt">34,994</span></td> <td style="padding-right: 1.45pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 5.4pt"><span style="font-size: 10pt">Comprehensive loss attributable to the Company</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_98F_eus-gaap--OciEquityMethodInvestmentBeforeTaxParent_pn3n3_c20220701__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_ze5Cyg3e3j4k" style="padding-right: 1.45pt; text-align: right" title="Comprehensive loss attributable to the company"><span style="font-size: 10pt">35,567</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_98B_eus-gaap--OciEquityMethodInvestmentBeforeTaxParent_pn3n3_c20220701__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zlDk0KhpPKR" style="padding-right: 1.45pt; text-align: right" title="Comprehensive loss attributable to the company"><span style="font-size: 10pt">(665</span></td> <td style="padding-right: 1.45pt"><span style="font-size: 10pt">)</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td id="xdx_987_eus-gaap--OciEquityMethodInvestmentBeforeTaxParent_pn3n3_c20220701__20230331_zbMZnDl5gef2" style="padding-right: 1.45pt; text-align: right" title="Comprehensive loss attributable to the company"><span style="font-size: 10pt">34,902</span></td> <td style="padding-right: 1.45pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCECFF"> <td style="padding-left: 5.4pt"><span style="font-size: 10pt">Loss per common share, basic and diluted</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_981_ecustom--EarningsLossPerShareBasicAndDiluted_pid_uUSDPShares_c20220701__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zWRnAaJET1i8" style="padding-right: 1.45pt; text-align: right" title="Loss per common share, basic and diluted"><span style="font-size: 10pt">1.26</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_98B_ecustom--EarningsLossPerShareBasicAndDiluted_pid_uUSDPShares_c20220701__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zf7OTzzqRKrl" style="padding-right: 1.45pt; text-align: right" title="Loss per common share, basic and diluted"><span style="font-size: 10pt">(0.02</span></td> <td style="padding-right: 1.45pt"><span style="font-size: 10pt">)</span></td> <td style="padding-right: 1.45pt"> </td> <td style="padding-right: 1.45pt"><span style="font-size: 10pt">$</span></td> <td id="xdx_988_ecustom--EarningsLossPerShareBasicAndDiluted_pid_uUSDPShares_c20220701__20230331_z8dneKmKuTV7" style="padding-right: 1.45pt; text-align: right" title="Loss per common share, basic and diluted"><span style="font-size: 10pt">1.24</span></td> <td style="padding-right: 1.45pt"> </td></tr> </table> <p id="xdx_8A0_z6LBYNyBTvh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"></p> <p id="xdx_892_esrt--ScheduleOfCondensedCashFlowStatementTableTextBlock_zAD57VdDtUPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Revision Impacts to the Condensed Consolidated Statement of Cash Flows (unaudited)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the Nine Months Ended March 31, 2023</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_8B5_z14eJLyY15d8" style="display: none; visibility: hidden">Revision Impacts to the Condensed Consolidated Statement of Cash Flows (unaudited) For the Nine Months Ended March 31, 2023</span> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">As Previously<br/> Reported</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">Revision<br/> Impacts</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">Revised</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 55%; text-align: left">Net loss for the period</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--NetIncomeLoss_pn3n3_c20220701__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zbiFHIIS78Sh" style="width: 12%; text-align: right">(35,741</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--NetIncomeLoss_pn3n3_dxL_c20220701__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zSvmIcP42Hzg" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1022">665</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--NetIncomeLoss_pn3n3_c20220701__20230331_zfmGaN4AcFT2" style="width: 12%; text-align: right">(35,076</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt">Initial valuation of warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--AssumptionOfPrivateAndPublicWarrants_pn3n3_c20220701__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zwjsL1DGD204" style="text-align: right">3,848</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--AssumptionOfPrivateAndPublicWarrants_pn3n3_c20220701__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zIqZuI2UrFOg" style="text-align: right">(861</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--AssumptionOfPrivateAndPublicWarrants_pn3n3_c20220701__20230331_zswoFw4mvRbh" style="text-align: right">2,987</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt">Change in fair value of warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220701__20230331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zUapaVmlhvAi" style="text-align: right">868</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220701__20230331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zbjfLsqFDSz4" style="text-align: right">196</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220701__20230331_zAf3FS7vazv5" style="text-align: right">1,064</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A7_zi5vEHv55UAd" style="margin-top: 0; margin-bottom: 0"></p> <p style="margin-top: 0; margin-bottom: 0"> </p>
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4638000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	34070000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-145381000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-11847000	usd
CY2023Q1	us-gaap	Other General Expense OtherGeneralExpense	25359000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	28331000	usd
CY2023Q1	niobf	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-980000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	28770000	usd
CY2023Q1	niobf	Profit Loss1 ProfitLoss1	28678000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	28658000	usd
CY2023Q1	us-gaap	Oci Equity Method Investment Before Tax Parent OciEquityMethodInvestmentBeforeTaxParent	28566000	usd
CY2023Q1	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	0.98
	us-gaap	Other General Expense OtherGeneralExpense	26027000	usd
	us-gaap	Operating Expenses OperatingExpenses	32614000	usd
	niobf	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-1064000	usd
	niobf	Profit Loss1 ProfitLoss1	34984000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	34994000	usd
	us-gaap	Oci Equity Method Investment Before Tax Parent OciEquityMethodInvestmentBeforeTaxParent	34902000	usd
	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	1.24
	us-gaap	Net Income Loss NetIncomeLoss	-35076000	usd
	niobf	Assumption Of Private And Public Warrants AssumptionOfPrivateAndPublicWarrants	2987000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1064000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-10887000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-4824000	usd
CY2023	niobf	Cash And Cash Equivalents At Carrying Value1 CashAndCashEquivalentsAtCarryingValue1	2341000	usd
CY2023	us-gaap	Capital Expenditure Discontinued Operations CapitalExpenditureDiscontinuedOperations	2350000	usd
CY2023Q2	us-gaap	Business Combination Separately Recognized Transactions Additional Disclosures Acquisition Costs BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts	2168000	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	392000	usd
CY2023Q2	niobf	Business Combination Separately Recognized Transactions Additional Disclosures Acquisition Cash Costs BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCashCosts	1996000	usd
CY2023Q2	us-gaap	Business Combination Separately Recognized Transactions Additional Disclosures Issuance Costs Not Expensed BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed	6715000	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Capital Lease Obligation BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation	2987000	usd
CY2023Q2	niobf	Earnout Shares Assumed At Fair Value EarnoutSharesAssumedAtFairValue	13195000	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Financial Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities	650000	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	23767000	usd
CY2023	us-gaap	Subsidiary Or Equity Method Investee Cumulative Percentage Ownership After All Transactions SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions	1	pure
CY2023Q2	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	848000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	839000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	856000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	850000	usd
CY2023Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1990000	usd
CY2022Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	115000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1324000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	654000	usd
CY2023Q2	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	101000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	48000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	48000	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Fair Value Disclosure AccountsPayableAndAccruedLiabilitiesFairValueDisclosure	28000	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3491000	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	817000	usd
CY2021Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	11700000	usd
CY2021Q1	us-gaap	Investment Interest Rate InvestmentInterestRate	0.085	pure
CY2021Q1	us-gaap	Other Commitment OtherCommitment	350000	usd
CY2021Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	9650000	usd
CY2021Q1	us-gaap	Common Unit Issued CommonUnitIssued	855800	shares
CY2023	us-gaap	Accelerated Share Repurchases Final Price Paid Per Share AcceleratedShareRepurchasesFinalPricePaidPerShare	9.70
CY2021Q1	us-gaap	Line Of Credit Facility Commitment Fee Amount LineOfCreditFacilityCommitmentFeeAmount	350000	usd
CY2023	niobf	Minimum Consent Payment At Inception MinimumConsentPaymentAtInception	200000	usd
CY2023	niobf	Asc470 Loss On Extinguishment ASC470LossOnExtinguishment	201000	usd
CY2023	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	1221000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	1622000	usd
CY2023	niobf	Additional Consent Paymentbooked AdditionalConsentPaymentbooked	300000	usd
CY2023	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	1922000	usd
CY2023	niobf	Schedule Of Warrant Valuation Table Textblock ScheduleOfWarrantValuationTableTextblock	<p id="xdx_89D_ecustom--ScheduleOfWarrantValuationTableTextblock_z8D7RFLrWh9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_ztl8jfAUOVqa">The change in the fair value of the Contingent Consent Warrants is presented below:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 50%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 8.65pt; text-align: justify; text-indent: -8.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 2.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 2.15pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 2.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; padding-left: 8.65pt; text-align: justify; text-indent: -8.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial valuation, September 25, 2022</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-right: 2.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-right: 2.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iS_c20220701__20230630_zPk9r8SH3Fwh" style="font: 10pt Times New Roman, Times, Serif; width: 19%; padding-right: 2.15pt; text-align: right" title="Initial valuation, at beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,221</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-right: 2.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 0.25in; text-align: justify; text-indent: -8.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in valuation</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 2.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_984_ecustom--ChangeInValuationOfWarrants_c20220701__20230630_zLY1DjA0Htmh" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 2.15pt; text-align: right" title="Change in valuation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">489</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt; padding-left: 8.65pt; text-align: justify; text-indent: -8.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation at June 30, 2023</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 2.15pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_987_eus-gaap--WarrantsAndRightsOutstanding_iE_c20220701__20230630_z5inbWDzyBp3" style="border-bottom: black 2.25pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 2.15pt; text-align: right" title="Valuation, at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,710</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table>
CY2022Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1221000	usd
CY2023	niobf	Change In Valuation Of Warrants ChangeInValuationOfWarrants	489000	usd
CY2023Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1710000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	633000	usd
CY2023Q1	us-gaap	Convertible Debt ConvertibleDebt	12153000	usd
	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	1962000	usd
	niobf	Principal And Accrued Interest Converted PrincipalAndAccruedInterestConverted	3554000	usd
CY2022Q2	us-gaap	Convertible Debt ConvertibleDebt	10561000	usd
CY2023Q2	us-gaap	Convertible Debt ConvertibleDebt	13000000	usd
CY2023Q2	us-gaap	Option Contract Indexed To Equity Settlement Number Of Shares Effect Of Change In Fair Value Of Share OptionContractIndexedToEquitySettlementNumberOfSharesEffectOfChangeInFairValueOfShare	58300	shares
CY2023Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	314465	shares
CY2023Q2	us-gaap	Offering Costs Partnership Interests OfferingCostsPartnershipInterests	2000000.0	usd
CY2023Q2	niobf	Share Issuance Cost ShareIssuanceCost	172000	usd
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1912940	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.20
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	370000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7800
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	295229	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.10
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	391212	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.40
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1596499	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.50
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	447500	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	13.30
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.00
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	392446	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.70
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1446400	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.27
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	578000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.95
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	265129	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.99
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	217771	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.87
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1541500	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.64
CY2023Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1541500	shares
CY2023Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1541500	shares
CY2023Q2	us-gaap	Share Price SharePrice	6.68
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.09
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0330	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0133	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0026	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.636	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.544	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.541	pure
CY2020Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1237645	shares
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.43
CY2021	niobf	Nordmin Warrants NordminWarrants	50000	shares
CY2021	niobf	Class Of Warrant Or Right Exercise Price Warrants November Financing ClassOfWarrantOrRightExercisePriceWarrantsNovemberFinancing	6.45
CY2021	niobf	Class Of Warrant Or Right Lind Iii Warrants ClassOfWarrantOrRightLindIIIWarrants	855800	shares
CY2021	niobf	Class Of Warrant Or Right Exercise Price Lind Warrants ClassOfWarrantOrRightExercisePriceLindWarrants	7.83
CY2021	niobf	Class Of Warrant Or Right April Private Placement ClassOfWarrantOrRightAprilPrivatePlacement	441211	shares
CY2021	niobf	Class Of Warrant Or Right Exercise Price April Private Placements ClassOfWarrantOrRightExercisePriceAprilPrivatePlacements	13.15
CY2021	niobf	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	-910628	shares
CY2021	niobf	Class Of Warrant Or Right Exercise Price Exercised ClassOfWarrantOrRightExercisePriceExercised	6.05
CY2021	niobf	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	-239845	shares
CY2021	niobf	Class Of Warrant Or Right Exercise Price Expired ClassOfWarrantOrRightExercisePriceExpired	5.89
CY2021Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1434183	shares
CY2021Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.36
CY2022	niobf	Class Of Warrant Or Right June Private Placement ClassOfWarrantOrRightJunePrivatePlacement	504614	shares
CY2022	niobf	Class Of Warrant Or Right Exercise Price June Private Placements ClassOfWarrantOrRightExercisePriceJunePrivatePlacements	8.54
CY2022	niobf	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	-87175	shares
CY2022	niobf	Class Of Warrant Or Right Exercise Price Exercised ClassOfWarrantOrRightExercisePriceExercised	6.05
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1851622	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.99
CY2023	niobf	Yorkville Financing Warrants YorkvilleFinancingWarrants	1789267	shares
CY2023	niobf	Class Of Warrant Or Right Exercise Price Warrants Yorkville Financing Warrants ClassOfWarrantOrRightExercisePriceWarrantsYorkvilleFinancingWarrants	8.94
CY2023	niobf	Gxii Warrants GxiiWarrants	15666626	shares
CY2023	niobf	Class Of Warrant Or Right Exercise Price Warrants Gxii Warrants ClassOfWarrantOrRightExercisePriceWarrantsGXIIWarrants	11.50
CY2023	niobf	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	-491211	shares
CY2023	niobf	Class Of Warrant Or Right Exercise Price Exercised ClassOfWarrantOrRightExercisePriceExercised	11.67
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	18816304	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	10.98
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	18816304	shares
CY2023	us-gaap	Class Of Warrant Or Right Reason For Issuing To Nonemployees ClassOfWarrantOrRightReasonForIssuingToNonemployees	The Company may elect to redeem the Public Warrants subject to certain conditions, in whole and not in part, at a price of $0.01 per Public Warrant if (i) 30 days’ prior written notice of redemption is provided to the holders, (ii) the last reported sale price of the Common Shares equals or exceeds approximately $16.10 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders
CY2023Q2	niobf	Amount Paid To Related Party AmountPaidToRelatedParty	1130000	usd
CY2022Q2	us-gaap	Related Party Deposit Liabilities RelatedPartyDepositLiabilities	2000000	usd
CY2021Q2	us-gaap	Related Party Deposit Liabilities RelatedPartyDepositLiabilities	2318000	usd
CY2023	niobf	Amounts Advanced AmountsAdvanced	1130000	usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-3130000	usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-318000	usd
CY2022Q2	us-gaap	Related Party Deposit Liabilities RelatedPartyDepositLiabilities	2000000	usd
CY2023	us-gaap	Exploration Expense ExplorationExpense	5348000	usd
CY2022	us-gaap	Exploration Expense ExplorationExpense	3309000	usd
CY2021	us-gaap	Exploration Expense ExplorationExpense	1056000	usd
CY2023	niobf	Discount Rate DiscountRate	0.16	pure
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	93	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	90	usd
CY2023	niobf	Fixed Rent Expense FixedRentExpense	83000	usd
CY2022	niobf	Fixed Rent Expense FixedRentExpense	83000	usd
CY2021	niobf	Fixed Rent Expense FixedRentExpense	106000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	13000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	12000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	7000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	10000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	16000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	13000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	33000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	26000	usd
CY2021	us-gaap	Sublease Income SubleaseIncome	18000	usd
CY2023	us-gaap	Lease Cost LeaseCost	73000	usd
CY2022	us-gaap	Lease Cost LeaseCost	85000	usd
CY2021	us-gaap	Lease Cost LeaseCost	108000	usd
CY2023	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	73000	usd
CY2022	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	85000	usd
CY2021	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	89000	usd
CY2021	us-gaap	Exploration Costs ExplorationCosts	19000	usd
CY2023	us-gaap	Lease Cost LeaseCost	73000	usd
CY2022	us-gaap	Lease Cost LeaseCost	85000	usd
CY2021	us-gaap	Lease Cost LeaseCost	108000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	71000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	96000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	98000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	50000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	315000	usd
CY2023Q2	niobf	Less Amount Of Payments Representing Interest LessAmountOfPaymentsRepresentingInterest	-80000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	235000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	71000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	164000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	40612000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	10887000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	4824000	usd
CY2023	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	40612000	usd
CY2022	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	10887000	usd
CY2021	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	4824000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	10965000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	2940000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	1303000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-131000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-72000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-31000	usd
CY2023	niobf	Earnout Shares Liability EarnoutSharesLiability	-2841000	usd
CY2023	niobf	Warrant Liability WarrantLiability	-1518000	usd
CY2023	niobf	Gxii Transaction Costs GxiiTransactionCosts	-925000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-412000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-462000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-212000	usd
CY2023	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	496000	usd
CY2022	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	407000	usd
CY2021	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	158000	usd
CY2023	us-gaap	Extinguishment Of Debt Gain Loss Income Tax ExtinguishmentOfDebtGainLossIncomeTax	-54000	usd
CY2023	niobf	Effect Of Legislative Changes EffectOfLegislativeChanges	-2000	usd
CY2022	niobf	Effect Of Legislative Changes EffectOfLegislativeChanges	-38000	usd
CY2021	niobf	Effect Of Legislative Changes EffectOfLegislativeChanges	182000	usd
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	14000	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-274000	usd
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	739000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	45000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	26000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	18000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-4341000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1713000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1841000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11893000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8977000	usd
CY2023Q2	niobf	Deferred Tax Assets Mineral Interest DeferredTaxAssetsMineralInterest	9477000	usd
CY2022Q2	niobf	Deferred Tax Assets Mineral Interest DeferredTaxAssetsMineralInterest	9477000	usd
CY2023Q2	niobf	Deferred Tax Assets Startup And Oorganizational Costs DeferredTaxAssetsStartupAndOorganizationalCosts	2132000	usd
CY2023Q2	niobf	Deferred Tax Assets Research And Development Costs DeferredTaxAssetsResearchAndDevelopmentCosts	1060000	usd
CY2023Q2	niobf	Deferred Tax Assets Share Issuance Costs DeferredTaxAssetsShareIssuanceCosts	446000	usd
CY2023Q2	niobf	Capital Losses Available For Future Periods CapitalLossesAvailableForFuturePeriods	419000	usd
CY2022Q2	niobf	Capital Losses Available For Future Periods CapitalLossesAvailableForFuturePeriods	420000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	36000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	74000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	25463000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18948000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25463000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18948000	usd
CY2022Q2	niobf	Increases In Capital Losses Available For Future Periods IncreasesInCapitalLossesAvailableForFuturePeriods	-221000	usd
CY2022	niobf	Other Income Taxes OtherIncomeTaxes	-3000	usd
CY2023Q2	niobf	Capital Loss Caryforward CapitalLossCaryforward	19000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18948000	usd
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17235000	usd
CY2023	niobf	Deferred Tax Assets Valuation Allowance Additions DeferredTaxAssetsValuationAllowanceAdditions	4341000	usd
CY2022	niobf	Deferred Tax Assets Valuation Allowance Additions DeferredTaxAssetsValuationAllowanceAdditions	1713000	usd
CY2023	us-gaap	Costs Incurred Development Costs CostsIncurredDevelopmentCosts	2174000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25463000	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18948000	usd
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	406000	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25463000	usd
CY2023Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	43758000	usd
CY2022Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	34011000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	2341000	usd
CY2023Q2	niobf	Available For Sale Securities Equity Securities Other AvailableForSaleSecuritiesEquitySecuritiesOther	9000	usd
CY2023Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	2350000	usd
CY2023Q2	us-gaap	Other Liabilities Fair Value Disclosure OtherLiabilitiesFairValueDisclosure	10521000	usd
CY2023Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	4989000	usd
CY2023Q2	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	15510000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	5280000	usd
CY2022Q2	niobf	Available For Sale Securities Equity Securities Other AvailableForSaleSecuritiesEquitySecuritiesOther	10000	usd
CY2022Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	5290000	usd
CY2023	dei	Auditor Name AuditorName	BDO USA, P.C.; Spokane, Washington; PCAOB ID#
CY2023	dei	Auditor Location AuditorLocation	Spokane, Washington
CY2023	dei	Auditor Firm AuditorFirmId	243

Files In Submission

Name	View Source	Status
niobf-20230630_cal.xml	Edgar Link	unprocessable
niobf-20230630_pre.xml	Edgar Link	unprocessable
0001539497-23-001700-index-headers.html	Edgar Link	pending
0001539497-23-001700-index.html	Edgar Link	pending
0001539497-23-001700.txt	Edgar Link	pending
0001539497-23-001700-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
n257410kimg001.jpg	Edgar Link	pending
n257410kimg002.jpg	Edgar Link	pending
n257410kimg003.jpg	Edgar Link	pending
n257410kimg004.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
n257410kimg005.jpg	Edgar Link	pending
n2574ex2310img001.jpg	Edgar Link	pending
n2574ex2311img001.jpg	Edgar Link	pending
n2574ex2312img001.jpg	Edgar Link	pending
n2574ex2313img001.jpg	Edgar Link	pending
n2574ex2314img001.jpg	Edgar Link	pending
n2574ex2315img001.jpg	Edgar Link	pending
n2574ex2315img002.jpg	Edgar Link	pending
n2574ex2316img001.jpg	Edgar Link	pending
n2574ex2317img001.jpg	Edgar Link	pending
n2574ex232img001.jpg	Edgar Link	pending
n2574ex233img001.jpg	Edgar Link	pending
n2574ex234img001.jpg	Edgar Link	pending
n2574ex235img001.jpg	Edgar Link	pending
n2574ex236img001.jpg	Edgar Link	pending
n2574ex236img002.jpg	Edgar Link	pending
n2574ex237img001.jpg	Edgar Link	pending
n2574ex238img001.jpg	Edgar Link	pending
n2574ex239img001.jpg	Edgar Link	pending
n2574_x163-10k.htm	Edgar Link	pending
n2574_x163ex21-1.htm	Edgar Link	pending
n2574_x163ex23-1.htm	Edgar Link	pending
n2574_x163ex23-10.htm	Edgar Link	pending
n2574_x163ex23-11.htm	Edgar Link	pending
n2574_x163ex23-12.htm	Edgar Link	pending
n2574_x163ex23-13.htm	Edgar Link	pending
n2574_x163ex23-14.htm	Edgar Link	pending
n2574_x163ex23-15.htm	Edgar Link	pending
n2574_x163ex23-16.htm	Edgar Link	pending
n2574_x163ex23-17.htm	Edgar Link	pending
n2574_x163ex23-2.htm	Edgar Link	pending
n2574_x163ex23-3.htm	Edgar Link	pending
n2574_x163ex23-4.htm	Edgar Link	pending
n2574_x163ex23-5.htm	Edgar Link	pending
n2574_x163ex23-6.htm	Edgar Link	pending
n2574_x163ex23-7.htm	Edgar Link	pending
n2574_x163ex23-8.htm	Edgar Link	pending
n2574_x163ex23-9.htm	Edgar Link	pending
n2574_x163ex31-1.htm	Edgar Link	pending
n2574_x163ex31-2.htm	Edgar Link	pending
n2574_x163ex32-1.htm	Edgar Link	pending
n2574_x163ex32-2.htm	Edgar Link	pending
n2574_x163ex4-25.htm	Edgar Link	pending
niobf-20230630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
niobf-20230630_def.xml	Edgar Link	unprocessable
niobf-20230630_lab.xml	Edgar Link	unprocessable
n2574_x163-10k_htm.xml	Edgar Link	completed
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NB
NIOCORP DEVELOPMENTS LTD Stock $nb

2023 Q4 Form 10-K Financial Statement

#000153949723001700 Filed on October 06, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NB NIOCORP DEVELOPMENTS LTD Stock $nb

2023 Q4 Form 10-K Financial Statement

#000153949723001700 Filed on October 06, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NB
NIOCORP DEVELOPMENTS LTD Stock $nb